Cerebrolysin 5 ml Neuroprotective Peptide Therapy: Usage, Effectiveness, Purchase
25 Mar 2026
The human brain is a complex network of neurons, constantly exposed to stress from aging, ischemic events, injuries, and neurodegenerative disorders. Loss of synaptic connections, reduced neuroplasticity, and oxidative stress may impair memory, attention, and motor function.
Cerebrolysin 5 ml is a neuropeptide-based therapy that stimulates neuronal recovery and supports cognitive function. It contains low-molecular-weight peptides and amino acids mimicking the action of natural neurotrophic factors such as BDNF and NGF.
Mechanism of Action
The drug acts on several levels:
- Neuroprotection: prevents neuronal apoptosis and oxidative damage.
- Neuroplasticity stimulation: promotes growth of new neurons and synapses, strengthens existing connections.
- Metabolic support: enhances cerebral microcirculation and glucose metabolism.
- Anti-inflammatory effects: reduces localized neuroinflammation.
📌 Key studies:
- Neurotrophic effects of Cerebrolysin: animal study on neuronal growth
- Cerebrolysin in stroke recovery: clinical trial results
Indications
Cerebrolysin is indicated for:
- Ischemic stroke improves recovery of motor and cognitive functions.
- Dementia and Alzheimer's disease slows cognitive decline, enhances memory.
- Traumatic brain injury accelerates recovery after injury.
- Chronic cerebral ischemia increases resilience to hypoxia and improves microcirculation.
Administration
- Intramuscular: 15 ml daily, course 1020 days.
- Intravenous: up to 50 ml, hospital use only in severe cases.
- Repeat course: after 23 months if needed.
Dosage and Treatment Scheme
- Initial dose: 5 ml intramuscularly.
- Standard course: 1020 days, as prescribed by a physician.
- Extended course: repeat after 23 months if required.
- Special considerations: dose adjustment for renal impairment or sensitivity.
Effectiveness Study Results
- Stroke: accelerates recovery and improves patient independence Cerebrolysin functional recovery after stroke.
- Dementia/Alzheimer's: improves cognitive function Clinical trial on Alzheimer's disease, Meta-analysis on Cerebrolysin in dementia.
- Traumatic brain injury: reduces neurological deficits Study on TBI recovery with Cerebrolysin.
Comparison with Other Drugs
| Drug | Effectiveness | Evidence Base |
|---|---|---|
| Cerebrolysin | High | RCTs, meta-analyses |
| Cortexin | Medium | Local studies |
| Actovegin | Medium | Limited clinical data |
| Piracetam | Low | Symptomatic only |
Side Effects and Safety
- Headache
- Dizziness
- Anxiety
- Allergic reactions (rare)
FAQ
- How long is the course? 1020 days.
- When are effects visible? first improvements after 57 days, significant changes in 23 weeks.
- Can it be used without medical supervision? only with a doctors prescription.
- Can it be combined with other nootropics? yes, under medical guidance.
Conclusion
Cerebrolysin 5 ml is one of the most studied neuroprotectors, with proven effectiveness in stroke, dementia, and brain injury recovery:
- Accelerates brain function recovery
- Improves cognitive performance
- Safe and well-tolerated
